miltefosine (Impavido)

Introduction

FDA-approved March 2014.

Indications

• treatment of leishmaniasis
  • visceral leishmaniasis
  • cutaneous leishmaniasis
  • mucocutaneous leishmaniasis

Contraindications

• pregnancy

Dosage

• oral

Adverse effects

• nausea
• vomiting
• diarrhea
• abdominal pain
• decreased appetite
• headache
• dizziness
• drowsiness
• itching
• increased serum transaminases
• increased serum creatinine

More general terms

• antiparasitic agent

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3599